RxDoctor Payments Data

Jacob Sellers, NP

Family · Savannah, GANPI 1326696071

Payments from drug & device makers

$11,723in general payments, 2019–2025

Across 593 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Actelion Pharmaceuticals US, Inc.$825
  • Boehringer Ingelheim$613
  • Insmed, Inc.$598
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$11,44598%
  • Education$2782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,723 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$20,879
Medicare patients
169
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter600$485,425
UptraviSelexipag12$279,273
Fasenra PenBenralizumab37$218,737
OpsumitMacitentan15$190,767
Breztri AerosphereBudesonide/Glycopyr/Formoterol212$161,371
NucalaMepolizumab28$119,860
Pirfenidone19$84,948
Breo ElliptaFluticasone/Vilanterol172$81,446
EliquisApixaban74$64,436
Dupixent PenDupilumab16$63,376
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr116$57,596
Tadalafil42$52,088
Stiolto RespimatTiotropium Br/Olodaterol Hcl62$45,891
SymbicortBudesonide/Formoterol Fumarate132$32,179
Spiriva HandihalerTiotropium Bromide36$26,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,968$750,780941 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$825$470,04127 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler, Bevespi Aerosphere$1,445$204,060377 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$613$84,308120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →